

Pharmacy Drug Policy Checklist

POLICY NAME Bylvay (odevixibat) POLICY # 3176P

Criteria

Coverage Criteria for Pruritus due to Familial Intrahepatic Cholestasis		
	 1.1 Diagnosis of pruritus (itching) due to progressive familial intrahepatic cholestasis (PFIC) Diagnosis confirmed by genetic testing showing biallelic pathogenic mutations in the ATP8B1 (ie, PFIC1) or ABCB11 (ie, PFIC2) genes 	
	 1.2 Member has cholestasis, as indicated by one of the following: Total serum bile acid >3 × upper limit of normal (ULN) for age Conjugated bilirubin >2 mg/dL Fat soluble vitamin deficiency that is otherwise unexplainable Gamma Glutamyl Transferase (GGT) >3 × ULN for age Intractable pruritus explainable only by liver disease 	
	1.3 Age 3 months or older	
	1.4 Prescribed by or in consultation with a hepatologist (liver doctor)	
	1.5 Documented concurrent use or previous trial and failure, intolerance or contraindication ursodiol and cholestyramine	
	1.6 Review of chart notes documenting diagnosis and confirming that the patient has met all of the above requirements for treatment with Bylvay by both a pharmacist and medical director	
Coverage Criteria for Pruritus due to Alagille Syndrome		
	2.1 Diagnosis of moderate to severe pruritus due to Alagille syndrome (ALGS)Diagnosis of ALGS confirmed by genetic testing showing pathogenic variants in the JAG1 or NOTCH2 genes	
	 2.2 Member has cholestasis, as indicated by one of the following: Total serum bile acid >3 × upper limit of normal (ULN) for age Conjugated bilirubin >2 mg/dL Fat soluble vitamin deficiency that is otherwise unexplainable Gamma Glutamyl Transferase (GGT) >3 × ULN for age Intractable pruritus explainable only by liver disease 	
	2.3 Age 12 months or older	
	2.4 Prescribed by or in consultation with a hepatologist (liver doctor)	

2.5 Documented trial and failure, contraindication or intolerance to TWO of the following:
• Ursodiol
• Rifampin
Cholestyramine
Sertraline
Naltrexone (not for pediatric patients)
2.6 Review of chart notes documenting diagnosis and confirming that the patient has met all of the above requirements for treatment with Bylvay by both a pharmacist and medical director

Exclusion Criteria – Any of the following prevents coverage		
	3.1 Genetic testing indicates PFIC with ABCB11 variants encoding for non-function or absence of BSEP-3	
	3.2 Pregnancy	
	3.3 Chronic diarrhea requiring consistent fluid or nutritional intervention	
	3.4 History of liver transplant or biliary diversion surgery within the past 6 months	
	3.5 Evidence of decompensated cirrhosis	
	3.6 Concurrent use with Livmarli	